Biogen Inc. (BIIB)
Summary
BIIB Chart
Why Is Biogen (BIIB) Up 6.5% Since Last Earnings Report?
Biogen (BIIB) reported earnings 30 days ago. What's next for the stock?
Should You Buy, Sell or Hold Biogen Stock After a 9% Rise in a Month?
BIIB's newer drugs, M&A activity and pipeline progress are fueling its turnaround, but declining MS sales remain a key risk.
Q2 Earnings Season in Full Swing
Pre-market futures are flat-to-down ahead of today's open, with overseas turbulence in the memory chip market reverberating on domestic shores. We also see something of a hesitation in trading ahead of this afternoon's Fed decision on interest rates.
Biogen Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| TJD Thomas John Drogan PR Inc.IPAL SECURITIES Inc. | 1,661 | $312,399.51 | $335,223.04 | $22,823.53 | 7.31% |
| LC Lisa Candera CIGNA INVESTMENTS Inc. /NEW | 1,395 | $195,319.15 | $283,115.25 | $87,796.1 | 44.95% |
 Curtis Ellergodt Rothschild Investment LLC | 909 | $146,913.28 | $187,508.52 | $40,595.24 | 27.63% |
| BZ Brandon Zatopek Commonwealth Equity Services LLC | 16,759 | $3.62M | $3.48M | -$136,085.54 | -3.76% |
| ABB Alexander Bjornager Bonde Danske Bank A/S | 66,365 | $12.44M | $13.8M | $1.36M | 10.95% |
Biogen Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Salim Syed Mizuho | 458.9 | $95,657.16 | $94,661.35 | -$995.81 | -1.04% |
Biogen Inc. (BIIB) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Biogen Inc. ever had a stock split?
Biogen Inc. Profile
| Biotechnology Industry | Healthcare Sector | Christopher A. Viehbacher CEO | NASDAQ (NGS) Exchange | 09062X103 CUSIP |
| US Country | 7,500 Employees | - Last Dividend | 18 Jan 2001 Last Split | 16 Sep 1991 IPO Date |
Overview
Biogen Inc. is a pioneering biopharmaceutical company focused on discovering, developing, manufacturing, and delivering innovative therapies for neurological and neurodegenerative diseases. With a broad international presence, Biogen extends its reach across the United States, Europe, Germany, Asia, and other global regions. Since its founding in 1978, Biogen has been at the forefront of addressing some of the most challenging medical conditions, including multiple sclerosis (MS), spinal muscular atrophy, Alzheimer's disease, and psoriasis, among others. The company operates in collaboration with several notable industry partners, such as Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; and others, to advance its mission of transforming scientific discoveries into medical breakthroughs. Headquartered in Cambridge, Massachusetts, Biogen's commitment to improving patient care continues to drive its innovative research and drug development strategies.
Products and Services
Biogen's diverse portfolio showcases its dedication to treating complex neurological and neurodegenerative conditions:
- TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA: These products are part of Biogen's multiple sclerosis (MS) treatment range, addressing various aspects of MS management to improve patient quality of life.
- SPINRAZA: A groundbreaking therapy for spinal muscular atrophy, offering hope to individuals affected by this genetic disorder.
- ADUHELM: Part of Biogen's Alzheimer's disease portfolio, this drug represents a significant advancement in treating a condition that affects millions of individuals worldwide.
- FUMADERM: Developed for the treatment of plaque psoriasis, demonstrating Biogen's commitment to addressing autoimmune skin conditions.
- Biosimilars (BENEPALI, IMRALDI, FLIXABI, BYOOVIZ): These etanercept, adalimumab, infliximab, and ranibizumab biosimilars offer cost-effective alternatives to some of the most widely used biologic therapies for autoimmune diseases and macular degeneration.
- RITUXAN (and RITUXAN HYCELA), GAZYVA, OCREVUS: Biogen's offerings in the oncology and MS spaces, including treatments for non-Hodgkin's lymphoma, CLL, rheumatoid arthritis, and primary progressive MS, highlight the company's strong presence in developing therapies for both cancer and autoimmune diseases.
- LUNSUMIO, glofitamab, and other anti-CD20 therapies: These therapies are designed for patients with relapsed or refractory follicular lymphoma and non-Hodgkin's lymphoma, showcasing Biogen’s ongoing dedication to innovative cancer treatment.
In addition, Biogen's pipeline includes a broad array of projects targeting MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease, neuropsychiatry, genetic neurodevelopmental disorders, and the development of biosimilars. These initiatives, under various stages of development, signify Biogen's enduring commitment to expanding its impact on unmet medical needs and improving the lives of patients around the globe.
